Skip to main content
SpringerLink
Log in

Biodistribution of Amphotericin B When Delivered Through Cholesterol Hemisuccinate Vesicles in Normal and A. Fumigatus Infected Mice

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. This study compared the biodistribution of two amphotericin B formulations in normal and Aspergillus infected mice. Amphotericin B cholesterol hemisuccinate vesicles (ABCV) which reduces the toxicity of amphotericin B and thereby enhances its therapeutic efficacy in a murine model of aspergillosis was compared with conventional amphotericin B deoxycholate suspension (AmBDOC).

Methods. ABCV (12 mg/kg wt) and AmBDOC (2 mg/kg wt) were intravenously administered to normal and A.fumigatus infected mice. The concentration of amphotericin B in plasma and other organs was determined at different time points.

Results. It was observed that ABCV had a significantly different pharmacokinetic profile compared to conventional amphotericin B. In comparison to AmBDOC significantly lower levels of amphotericin B were observed in kidneys and plasma, the major target organs of toxicity. Animals receiving ABCV demonstrated high levels of amphotericin B in liver (38% retention till 48 h) and spleen (2.6% retention till 48 h) in comparison to AmBDOC (7.3% and 0.21% retention in liver and spleen respectively till 48 h). Biodistribution studies of ABCV in infected mice demonstrated that there was a moderate enhancement in levels of amphotericin B in liver, spleen, lungs and kidneys as compared to normal mice and the plasma levels were reduced. However, such observations were not made after AmBDOC administration to infected mice except for kidneys in which there was a marked increase in uptake as compared to normal mice.

Conclusions. Our results suggest that prolonged retention of high concentrations of ABCV in reticuloendothelial system organs is the reason for its reduced toxicity. Enhanced localization of the drug at the infected site may lead to improvement in therapeutic efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. G. Medoff, J. Brajtburg, G. S. Kobayashi, and J. Bolard. Antifungal agents useful in therapy of systemic fungal infections. Annu. Rev. Pharmacol. Toxicol. 23:303–330 (1983).

    Google Scholar 

  2. B. Dekruyff, W. J. Gerristen, A. Oerlemans, R. A. Demel, and L. L. M. Van Deenen. Polyene antibiotic-sterol interactions in membrane of Acholeplasma ladlawii cells and lecithin liposomes. I. Specificity of the membrane permeability changes induced by polyene antibiotics. Biochim. Biophys. Acta 339:30–43 (1974).

    Google Scholar 

  3. D. W. Denning and D. A. Stevens. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases. Rev. Infect. Dis. 12:1147–1201 (1990).

    Google Scholar 

  4. M. S. Maddux and S. L. Barriere. A review of complications of amphotericin B therapy: Recommendations for prevention and management. Drug Intell. Clin. Pharm. 14:177–181 (1980).

    Google Scholar 

  5. J. W. Hiemenz and T. J. Walsh. Lipid formulations of amphotericin B: Recent progress and future directions. Clin. Infect. Dis. 22:133–144 (1996).

    Google Scholar 

  6. R. Janknegt, S. De Marie, I. A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. Liposomal and lipid formulations of amphotericin B: Clinical pharmacokinetics. Clin. Pharmacokinet. 23: 279–291 (1992).

    Google Scholar 

  7. S. De Marie, R. Janknegt, and I. A. J. M Bakker-Woudenberg. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33:907–916 (1994).

    Google Scholar 

  8. I. Bekersky, R. M. Fielding, D. Buell, and I. Lawrence. Lipid-based amphotericin B formulations: From animals to man. Pharmaceut. Sci. Technol.Today. 2:230–236 (1999).

    Google Scholar 

  9. J. M. Clark, R. R. Whitney, S. J. Olsen, R. J. George, M. R. Swerdel, L. Kunselman, and D. P. Bonner. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35:615–621 (1991).

    Google Scholar 

  10. R. M. Fielding, P. C. Smith, L. H. Wang, J. Porter, and L. S. S. Guo. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35:1208–1211 (1991).

    Google Scholar 

  11. L. S. S. Guo, R. M. Fielding, and D. D. Lasic. Novel antifungal drug delivery: Stable amphotericin B–cholesteryl sulfate discs. Int. J. Pharm. 75:45–54 (1991).

    Google Scholar 

  12. J. A. Gondal, R. P. Swartz, and A. Rahman. Therapeutic evaluation of free and liposomal encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33:1544–1548 (1989).

    Google Scholar 

  13. S. J. Olsen, M. R. Swerdel, B. Barbara, J. M. Clark, and D. P. Bonner. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43:831–835 (1991).

    Google Scholar 

  14. R. M. Fielding, A. W. Singer, L. H. Wang, S. Babbar, and L. S. S. Guo. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36:299–307 (1992).

    Google Scholar 

  15. S. Saxena, J. A. Khan, and P. C. Ghosh. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemi-succinate vesicles in the treatment of experimental murine aspergillosis. J. Antimicrob. Chemother. 42:635–642 (1998).

    Google Scholar 

  16. N. Munshi, K. Chakarvorty, T. K. De, and A. N. Maitra. Activity and stability studies of ultrafine nonoencapsulated catalase and penicillinase. Colloid Polymer Science 276:462–472 (1995).

    Google Scholar 

  17. I. Nilsson-Ehle, T. T. Yoshikawa, J. E. Edwards, M. C. Schotz, and B. G Lucien. Quantitation of amphotericin B with use of high-pressure liquid chromatography. J. Infect. Dis. 135:414–422 (1977).

    Google Scholar 

  18. J. Wartak. Clinical Pharmacokinetics, Prager Publishers. New York, 1983.

    Google Scholar 

  19. V. M. Vasandani, S. Madan, and P. C. Ghosh. In vivo potentiation of ricin toxicity by monensin delivered through liposomes. Biochim. Biophys. Acta 1116:315–323 (1992).

    Google Scholar 

  20. C. Kirby, J. Clarke, and G. Gregoriadis. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J. 186:591–598 (1980).

    Google Scholar 

  21. I. Ahmad, A. K Sarkar, and B. K. Bachhawat. Mannosylated liposome-mediated delivery of amphotericin-B in the control of experimental aspergillosis in balb/c mice. J. Clin. Biochem. Nutrition 10:171–179 (1991).

    Google Scholar 

  22. L. H. Wang, R. M. Fielding, P. C Smith, and L. S. S. Guo. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (amphocil) and fungizone after repeated dosing in rats. Pharm. Res. 12:275- 283 (1995).

    Google Scholar 

  23. J. W. Lee, M. A. Amantea, P. A. Francis, E. E. Navarro, J. Bacher, P. A Pizzo, and T. J. Walsh. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (am-Bisome) in rabbits. Antimicrob. Agents Chemother. 38:713–718 (1994).

    Google Scholar 

  24. R. M. Fielding, R. O. Lewis, and L. Moon-McDermott. Altered tissue distribution and elimination of amaikacin encapsulated in unilamellar, low-clearance liposomes (mikasome). Pharm. Res. 15:1775–1781 (1998).

    Google Scholar 

  25. J. R. Morgan, L. A. Williams, and C. B. Howard. Technetium-labeled liposome imaging for deep-seated infection. Br. J. Radiol. 58:35–39 (1985).

    Google Scholar 

  26. M. J. Ostro. Liposomes, Marcel Dekker, Inc. New York, 1983.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, University of Delhi South Campus, Benito Juarez Road, New Delhi-, 110021, India

    Sandeep Saxena

  2. Department of Biochemistry, University of Delhi South Campus, Benito Juarez Road, New Delhi-, 110021, India

    Prahlad C. Ghosh

Authors
  1. Sandeep Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prahlad C. Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saxena, S., Ghosh, P.C. Biodistribution of Amphotericin B When Delivered Through Cholesterol Hemisuccinate Vesicles in Normal and A. Fumigatus Infected Mice. Pharm Res 17, 1236–1242 (2000). https://doi.org/10.1023/A:1026418814417

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026418814417

Search

Navigation